When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.
Read original at benzingaStocks · News reference
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 8:19 PM
- Checked
- Aug 11, 2026, 8:19 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.
Read original at benzingaSELLAS Says Arbitrator Dismisses Its Claims Against 3D Medicines, Orders SELLAS To Pay Approximately $1M In Legal Fees
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001390478/000110465926087110/tm2621415d1_8k.htm
Read original at benzinga